Thematics Asset Management Has $4.71 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Thematics Asset Management trimmed its stake in Exact Sciences Co. (NASDAQ:EXAS) by 16.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,121 shares of the medical research company’s stock after selling 14,095 shares during the period. Thematics Asset Management’s holdings in Exact Sciences were worth $4,709,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its holdings in shares of Exact Sciences by 35.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 136,592 shares of the medical research company’s stock worth $9,305,000 after purchasing an additional 35,927 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in Exact Sciences by 12.8% in the third quarter. Daiwa Securities Group Inc. now owns 14,147 shares of the medical research company’s stock valued at $964,000 after buying an additional 1,600 shares in the last quarter. Cerity Partners LLC grew its stake in Exact Sciences by 193.8% during the third quarter. Cerity Partners LLC now owns 16,329 shares of the medical research company’s stock worth $1,112,000 after buying an additional 10,772 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Exact Sciences by 10.9% during the third quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock worth $169,924,000 after buying an additional 245,980 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Exact Sciences by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after acquiring an additional 45,015 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Trading Up 9.9 %

Shares of EXAS stock traded up $5.46 on Tuesday, reaching $60.60. The company had a trading volume of 1,315,658 shares, compared to its average volume of 2,636,848. The stock has a market cap of $11.22 billion, a PE ratio of -50.69 and a beta of 1.27. The company has a 50-day moving average of $64.51 and a 200-day moving average of $55.85. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The company’s revenue was up 12.8% compared to the same quarter last year. On average, equities analysts forecast that Exact Sciences Co. will post -1.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Kevin T. Conroy acquired 19,500 shares of Exact Sciences stock in a transaction dated Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the sale, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on EXAS. The Goldman Sachs Group decreased their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Robert W. Baird decreased their target price on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. BTIG Research cut their price target on Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. TD Cowen reduced their price target on shares of Exact Sciences from $90.00 to $82.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Benchmark lowered their price objective on shares of Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $74.47.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.